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ABSTRACT
Introduction: Misuse of opioid analgesics, in
combination with diversion, dependence, and
fatal overdoses, presents a serious problem for
public health, which affects many countries
worldwide. Within this context, tampering with
opioids has been associated with serious harm.
The aim of the present study was to assess the
tampering potential of codeine combination
analgesics on the market (containing codeine/
non-opioid analgesics) by the extraction of
codeine.
Methods: Codeine was extracted from three
combination formulations sold lawfully from
licensed pharmacies without a medical
prescription in Denmark and the UK.
Extraction of codeine followed tampering
procedures available on the Internet. The
amounts of codeine and accompanying
non-opioid analgesics in tampering products
were analysed with liquid chromatography and
tandem mass spectrometry (LC–MS/MS).
Results: LC–MS/MS showed recoveries of the
total amounts of codeine in tampering products
of 81–84% from Product 1 (codeine/
acetylsalicylic acid); 61–67% from Product 2
(codeine/ibuprofen); and 42–71% from Product
3 (codeine/paracetamol). Recoveries of
non-opioid analgesics ranged between:
57–73% acetylsalicylic acid; 5.5–8.5%
ibuprofen, and 5.0–9.2% paracetamol.
Conclusion: With the tampering procedures
used, high amounts of codeine were separated
from the accompanying analgesics in some, but
not in all of the codeine containing
formulations. Evidence-based medicine
regulation, treatment for opioid dependence,
and information to minimise risks to the public
are essential components of an effective public
health strategy to address the harms of
tampering and misuse.
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INTRODUCTION
If you take too much paracetamol, it’s going to
kill you. So what I would do is I would put
about 30 co-codamol tablets, 8 mg codeine
over 500 mg paracetamol, into a bottle and fill
it up with water. I would put that in the freezer
until the paracetamol crystals formed. Then I
poured out the liquid through a coffee filter so
you ended up with pure codeine water.
Patient (male, 34 years), in recovery-oriented
drug treatment in the UK, reporting of
tampering with codeine containing analgesics.
(Interview conducted May 2015 by the first
author with ethical approval granted by the
NRES Committee London, London Bridge
(REC reference: 15/LO/0107). Patient consent
was obtained).
Concerns have been growing in recent years
amongst public health bodies, medicines
regulators, and health professional groups in
Europe over the increasing use of opioid
analgesics and the associated risks of diversion,
misuse, dependence, and fatal overdoses [1–5].
Misuse of opioids is not a homogeneous
problem across Europe and the collection of
data remains poor [5, 6]. Despite this, specific
problems identified include the diversion of
methadone and buprenorphine from opioid
substitution treatment use [7–9] and diversion
of fentanyl from the appropriate use as
analgesics [2]. An increase in the rates of
deaths involving controlled prescription
opioids has been recorded in European
countries in recent years [10–12], along with
outbreaks of fentanyl-related deaths in the UK,
Germany, Sweden, and Finland [2]. A 176%
raise in deaths involving tramadol was recorded
from 2009 to 2014 in the UK [13]. Data show a
decline in new drug treatment demand from
clients using heroin, yet over 10% of opioid
clients entering services in 11 European
countries in 2013 were entrants for
prescription drugs such as methadone,
buprenorphine, and fentanyl [14].
Against this background, tampering of
medicines poses additional complications. There
are now a growing number of reports that
experimental users have found different ways of
manipulating with various opioid analgesics to
enhance their psychoactive effects, eliminate
undesirable components (drugs and excipients),
and bypass tampering-resistant formulations
[7, 15–17]. Tampering has been linked to serious
harm—for example, from snorting crushed
buprenorphine tablets [18], intravenously
injecting morphine and buprenorphine tablets
dissolved in water [15, 18], and oral consumption
of whole transdermal fentanyl patches [16, 17].
Misuse of and tampering with codeine has also
been identified [19–22].
Codeine, an opioid used in treatment of
pain, coughing, and diarrhoea, is supplied with
a prescription, but is also sold lawfully from
licensed pharmacies without a medical
prescription (‘over-the-counter’) in European
countries such as France, Denmark, Ireland,
Bulgaria, Poland, and the UK [23, 24].
Formulations sold ‘over-the-counter’ contain a
low amount of codeine in combination with a
non-opioid analgesic, such as paracetamol or
ibuprofen. An accompanying analgesic is
included to achieve an increased effect on the
relief of pain; however, adverse events from
prolonged and excessive use of codeine
combination analgesics have been reported,
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including gastrointestinal disease and
nephrotoxicity associated with ibuprofen and
paracetamol consumption [25–28]. Because
codeine is often misused through oral
administration of combination tablets
[19, 29, 30], tampering procedures which
separate codeine from the accompanying
analgesics appears to be gaining popularity
amongst certain codeine taking populations,
particularly in Internet savvy users [20, 22].
Often referred to as ‘cold water extraction’, the
aim is to keep as much codeine as possible in
the extracted tampering products, while at the
same time reducing the amount of non-opioid
analgesics to non-toxic levels.
Whilst the number of individuals who
routinely extracts codeine is unknown, use of
‘cold water extraction’ procedures have been
reported by individuals from drug treatment
services [31, 32], hospitals [33], and online
communities [20, 22]. Detailed descriptions of
‘cold water extraction’ can be found on drug
discussion forums on the Internet, such as
Erowid and Bluelight, but have also found their
way onto mainstream sites like YouTube where
some videos of codeine extraction have more
than 500,000 views [34]. Tampering of codeine
appeals to recreational users consuming high
amounts of codeine to induce opioid euphoria,
to codeine dependent concerned with the
toxicity of non-opioid analgesics, and to those
unable to obtain potent prescription opioids
who may turn to codeine to prevent
withdrawal and cravings [35]. Information on
dependence upon codeine is sparse, however,
case reports and research studies have identified
what seems to be a growing number of codeine
dependent across Europe [19, 21, 29, 36–38].
Furthermore, an increase of nearly 50% in the
distribution of codeine to the retail link between
1994 and 2013 [39], combined with
‘over-the-counter’ sales, is associated with
widespread use of codeine. In this landscape of
availability, individuals seeking to tamper with
codeine can obtain multiple packages relatively
unproblematic, such as from ‘pharmacy
shopping’ [29, 36, 40].
Misuse of prescription opioids has brought
into focus the risks of tampering. Sellers et al.
[41] examined the attractiveness of different
opioids for tampering amongst users. In
another study, users were asked to tamper
with prescription opioid tablets to assess
whether tablets could be converted into forms
amenable for snorting or injecting [42]. One
study investigated the chemical synthetic
pathways utilised in the illicit manufacturing
of morphine and heroin from codeine
formulations in ‘underground labs’ and
measured the quantitative yields of such
production [43]. The consequences of
tampering with codeine are potentially
wide-reaching, yet poorly researched. One
2003 study investigated the use of Internet
procedures for codeine extraction [44], but
included only one codeine formulation
(codeine/paracetamol). A study from 1993 also
examined the degree of separation after
tampering with a single tablet of three
different formulations with the use of
laboratory equipment [45]. Important as the
results of this study might be, they do not
necessarily apply to the current situation
because users typically extract codeine from 20
to 40 tablets at a time, using kitchen utensils
and common household appliances [20]. Thus,
the aim of the present study was to assess the
tampering potential of codeine combination
analgesics on the market in Denmark and the
UK by the extraction of codeine. ‘Cold water
extraction’ procedures from the Internet were
used to extract codeine [46–48].
High-performance liquid chromatography with
tandem mass spectrometry (LC–MS/MS)
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measured the amounts of codeine and
accompanying non-opioid analgesics in
tampering solutions.
METHODS
Selection of ‘Cold Water Extraction’
Procedures
The words ‘cold water extraction’ and ‘codeine’
were used to search the Internet for methods of
tampering. One search was conducted on
known drug discussion forums; another was
conducted with the use of a web search engine
(Google). For each identified procedure,
screenshots captured the mains steps involved
in codeine extraction. The screenshots were
then used to select procedures that (1) recently
had been commented on by forum or website
users, which is likely to provide a measure of
current use; and (2) made reference to specific
formulations—brands or generics—in order to
match specific tampering procedures with
specific codeine combination analgesics. Three
‘cold water extraction’ procedures from the
Internet were chosen for the study [46–48] and
matched with three different formulations.
Selection of Codeine Containing
Analgesics
Out of an array of low-strength codeine
formulations authorised for sale without a
medical prescription in Denmark and the UK,
three were chosen for this study: One sold in
Denmark, two sold in the UK (Table 1). The
Danish product contained 9.6 mg codeine
phosphate hemihydrate, 500 mg acetylsalicylic
acid, and 150 mg magnesium oxide (Product 1).
Current regulation permits the sale of this
product from pharmacies without a
prescription, but also from retail outlets, such
as supermarkets and petrol stations, without the
supervision of a pharmacist. The products sold
in the UK contained 12.8 mg codeine
phosphate hemihydrate and 200 mg ibuprofen
(Product 2), and 8 mg codeine phosphate
hemihydrate and 500 mg paracetamol (Product
Table 1 Codeine containing analgesics used toward codeine extraction
Product
number
Product
sold in
(Denmark/
UK)
Amount of codeine
phosphate
hemihydrate/tableta
(mg)
Amount of
codeine
free-base/
tablet (mg)
Amount of
accompanying
analgesics/tableta
Number of
tablets used
for
extraction
Total amounts of
codeine free-base
available for
extraction (mg)
1 Denmark 9.6 7.07 500 mg
acetylsalicylic
acid, 150 mg
magnesium
oxide
16 113.2
2 UK 12.8 9.43 200 mg ibuprofen 12 113.2
3 UK 8 5.89 500 mg
paracetamol
19 112.0
a As reported by the drug manufactures on the packaging and in the patient-information leaﬂets
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3). The codeine/paracetamol formulation was a
generic medicine and the cheapest available at a
price of less than £1.50 for 32 tablets.
Codeine Extraction
A study protocol was made which followed the
Internet procedures closely (Table 2). Extraction
of codeine from Product 1 (codeine/
acetylsalicylic acid) and Product 2 (codeine/
ibuprofen) was repeated in triplicate. Extraction
of codeine from Product 3
(codeine/paracetamol) was repeated eight
times to assess variation in the amounts of
codeine and paracetamol. For each attempt at
extraction, tablets containing a total amount of
approximately 150 mg of codeine phosphate
hemihydrate were used. This dose was generally
considered a ‘beginner’s dose’ on many websites
where dosage regimens were determined by
self-experimentation, but sometimes adjusted
according to age, body weight, and opioid
tolerance. ‘Cold water extraction’ is made
possible by the variation in solubility between
codeine (highly soluble in water) and
paracetamol, ibuprofen, and acetylsalicylic
acid (poorly soluble in water). However, the
concrete stages involved in codeine extraction
are briefly described below.
Extraction of Codeine from Product 1
(Codeine/Acetylsalicylic Acid)
With the use of a mortar, tablets were crushed
into a fine powder and mixed with water and
ordinary household citric acid (95–100%,
Matas, Denmark). In accordance with the
Internet procedure [46], 12 g citric acid were
added, which was supposed to enhance
precipitation of acetylsalicylic acid so that it
can be removed by filtration. However, adding
citric acid in order to improve separation did
not have the desired effect as the tampering
products contained high amounts of
acetylsalicylic acid. The solution was filtrated
with the use of a coffee filter (Non-bleached,
size 1 9 4; Abena, Denmark).
Extraction of Codeine from Product 2
(Codeine/Ibuprofen)
Tablets were submerged in water, mixed
thoroughly, and left in the refrigerator. After
an hour, a thick, white layer containing tablet
fillers and ibuprofen was left at the bottom of
the container, whereas a clear, aqueous layer of
codeine was harvested with a pipette from the
top of the container. In keeping with the
Internet procedure, water was added to the
substance consisting of tablet fillers and
ibuprofen for another round of extraction of
any remaining codeine.
Extraction of Codeine from Product 3
(Codeine/Paracetamol)
Tablets were placed in water and heated in a
water bath. Next, the solution was filtered using
a coffee filter and left in the freezer until the
temperature was below 2 C. After this, the
solution was filtered a second time. Similar to
the procedure used for Product 1, the highly
soluble codeine is supposed to flow through the
filter in aqueous form, the poorly soluble
paracetamol in solid form is not. For samples
6–8, the procedure was amended, leaving out
the use of a heated water bath. Here, tablets
were placed in water, after which the mixture
was stirred for 15 min and put in the freezer
until the temperature reached 1 C. This time,
the mixture was filtered only a single time.
Analysis of Tampering Solutions
Extraction and analysis of the tampering
products were conducted at the Department of
Clinical Biochemistry, North Denmark Regional
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Table 2 ‘Cold water extraction’ tampering procedures from the Internet
Examples of text from site Study protocol
Extraction of codeine from Product 1 (codeine/acetylsalicylic acid/magnesium oxide)
‘‘The ﬁrst thing to do is crush the tablets in a mortar’’
‘‘Add approximately 3 mL water for each tablet you use,
along with 0.55 g of citric acid per tablet’’
‘‘IMPORTANT! If you use the tablets containing 150 mg
magnesium oxide despite the risk of diarrhoea, you will
need to use 0.75 g of citric acid per tablet’’
‘‘Pour the solution with citric acid into the mortar containing
the crushed tablets, or pour the tablets into the container
with the citric acid. Stir thoroughly for about 5–10 min’’
‘‘Measure the pH of the solution. If it isn’t below 3.5, more
citric acid should be added’’
‘‘Next, the mixture is ﬁltered. The solution now contains
nearly all the codeine from the tablets, but almost none of
the acetylsalicylic acid’’
‘‘Citric acid is used because it prevents acetylsalicylic acid
from transforming into its salt, whereby precipitation is
ensured’’
16 tablets are crushed in a mortar
48 mL water (20C) is poured into a container, along with
12 g citric acid
The crushed tablets are added to the container containing
water and citric acid
The mixture is stirred for 10 min using a glass spatula
The pH is measured
The solution is ﬁltrated, using a coffee ﬁlter
Extraction of codeine from Product 2 (codeine/ibuprofen)
‘‘The tablets are removed from the package and dropped into
a small amount of warm water. Once the tablets have
absorbed the water, they will swell up and can now be easily
mixed with a fork. At this point, the product is ready for
extraction’’
‘‘The container is topped up with cold water and the mixture
is agitated to help dissolve the codeine’’
‘‘After around 30 min the mixture will have settled, leaving
the insoluble ibuprofen and binders at the bottom, and the
aqueous codeine solution at the top of the container’’
‘‘Using a syringe or dropper, the aqueous layer is harvested
into another container. A second pull using half the original
volume of water is then carried out in order to retrieve any
remaining codeine’’
12 tablets are submerged into 50 mL water (20C)
Tablets are mixed with a glass spatula
100 mL water is added (10C)
The solution is left in the refrigerator for an hour
The supernatant codeine solution is recovered with a
pipette
50 mL water (10C) is added to the remaining mixture
containing ibuprofen and tablet ﬁllers
The container is left in the refrigerator for an hour and a
half
The supernatant codeine solution is recovered with a
pipette, and added to the codeine containing solution
previously extracted
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Hospital, Denmark. High-performance liquid
chromatography with tandem mass
spectrometry (LC–MS/MS) was used to
determine the concentrations of codeine,
acetylsalicylic acid, ibuprofen, and
paracetamol after dilution of the tampering
solutions. Quantification was based upon
isotope dilution with deuterated internal
standards of the target compounds.
Calibration curves were constructed by
analysis of pure reference standards.
Intra-assay imprecision and bias was below
10%. The concentration of magnesium (Mg2?)
in tampering solutions derived from Product 1
was determined with inductively coupled
plasma atomic emission spectroscopy
(ICP-AES) at an ISO 15189 accredited external
laboratory, using the European standard
method EN ISO 11885 for determination of
selected elements in water.
Compliance with Ethics Guidelines
The study presented in this paper examined the
content of tampering solutions extracted from
codeine formulations using LC–MS/MS. The
aim was to assess the tampering potential.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors. No drugs were administered
in the study and medicines and resulting waste
were disposed of in safe and secure manner.
However, ethical issues were identified. It is
recognised that no licensed medicines
containing opioid analgesics can completely
withstand tampering attempts by experienced
users. Examining drug discussion forums on the
Internet, it is also clear that users adopt, and
disseminate, a range of tampering techniques
they believe can be applied with varying degrees
of success. Tampering of codeine is no
Table 2 continued
Examples of text from site Study protocol
Extraction of codeine from Product 3 (codeine/paracetamol)
‘‘Added 96 10 mg codeine 500 mg ? rubbish tablets to
200 mL cold tap water and left for 10 min or so to dissolve
CP’’
‘‘So I heated the solution in a hot water bath to about 45 or
50C’’
‘‘I then ﬁltered the solution and it ﬁltered in a fraction of the
time it usually does with cold water’’
‘‘This is then placed in the freezer until it almost freezes, by
which time almost all of the paracetamol dissolved,
crystalizes out in lovely large needle shaped crystals’’
‘‘This near frozen solution is then ﬁltered, which is also fast as
paracetamol crystals are now large. This solution is now safe
to drink’’
Procedure for samples 1–5
19 tablets are submerged in 40 mL tap water (10C)
After 10 min, the mixture is heated in a water bath until
the temperature reaches 45C
The solution is ﬁltered using a coffee ﬁlter
The ﬁltrate is placed in the freezer until the temperature is
below 2C
The solution is ﬁltered a second time, using a coffee ﬁlter
Procedure for samples 6–8
19 tablets are submerged in 100 mL tap water (24.5C)
The mixture is stirred for 15 min, until all tablets are
dissolved
The mixture is placed in the freezer, until the temperature
reaches 1C
The mixture is ﬁltered, with the use of a coffee ﬁlter
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exception [46–48]. Still published research
findings of assessments of harm, medicine
misuse, and tampering will in some cases
provide an additional outlet for tampering,
offering insights into types of opioids
tampered with, specific methods and tools
used for tampering, how well formulations can
be tampered with, and uptake of tampering
solutions by the body [41, 42, 44, 49, 50]. It will
come as no surprise to researchers frequenting
drug discussion forums that published data are
cited amongst users as evidence of which drugs
(or way of using drugs) gives the desired effects.
However, we would suggest that this is no
reason for inaction when it comes to the
difficult issues of medicine misuse. Arguably, it
is because of a failure to act in the first place that
tampering is now established as a serious
problem to public health [51]. Investigations
of misuse liability and tampering potential for
medicines on the market have an important
role to play in the pharmacovigilance system—
regardless of how the results of such research are
used by the public. Not only do they serve to
confirm the efficacy of tampering techniques
being used by the public but they also can
reveal related risks and help identify potential
risk reduction strategies for medicine regulators
and the pharmaceutical industry.
While the present study did not require
ethics approval, consultation was sought with
the Research Ethics Office, Psychiatry, Nursing
and Midwifery Research Ethics Subcommittees
(PNM RESC), King’s College London. The
Danish Health and Medicines Agency was also
informed of the study.
RESULTS
LC–MS/MS showed a recovery of the total
amounts of codeine in the final tampering
products in the range of 81–84% from Product
1 (codeine/acetylsalicylic acid), 61–67% from
Product 2 (codeine/ibuprofen), and 42–71%
from Product 3 (codeine/paracetamol) (Table 3).
The total amounts of codeine in the tampering
solutions ranged from 47 to 95 mg free-base
codeine (Table 3), with the largest quantity of
codeine found in a tampering product procured
from Product 1 (codeine/acetylsalicylic acid) and
the lowest in a tampering product from Product
3 (codeine/paracetamol).
Analyses showed that between 57% and 73%
of the total amounts of acetylsalicylic acid were
still present in the tampering products derived
from Product 1. The quantities ranged between
4570 and 5851 mg acetylsalicylic acid, which
was the highest amount of any of the
accompanying analgesics, measured in any of
the tampering solutions. In addition,
magnesium ions (Mg2?) were present in the
tampering solutions derived from Product 1 in
amounts equivalent to a recovery of 82–83%.
However, the tampering products procured
from the remaining codeine formulations
contained low amounts of both ibuprofen and
paracetamol. Here recoveries were in the range
of 5.5–8.5% ibuprofen (Product 2) and 5.0–9.2%
paracetamol (Product 3) (Table 3).
DISCUSSION
The results from the study show that it was
possible to separate relatively large amounts of
codeine from the accompanying non-opioid
analgesics in two out of the three codeine
containing medicines, albeit the percentages
of extracted codeine and non-opioid analgesics
in the tampering solutions varied. Based on the
drug recovery percentages achieved in the
study, as much as 1300 mg free-base codeine
can be consumed from tampering solutions
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procured from Product 2 without exceeding the
maximum dose of 2400 mg ibuprofen daily
[recommendations by the British National
Formulary (BNF) [52]]. This is five times the
daily recommended dose of codeine, according
to BNF guidelines [53]. From tampering
products procured from Product 3, up to about
500 mg of free-base codeine can be consumed
without exceeding the BNF stated 24 h limit of
4000 mg paracetamol [54]. However, the
remaining quantities of acetylsalicylic acid in
the tampering solutions procured from Product
1 (4570–5851 mg acetylsalicylic acid) exceeded
the recommended dose of maximum 4000 mg
acetylsalicylic acid in a day (BNF
recommendations) [55]. These findings are
important to the post-marketing surveillance
of opioids with misuse liability [56], in this case,
highlighting the lack of barriers toward
tampering in low-strength codeine
formulations. The ‘discovery’ of the tampering
possibilities of codeine containing analgesics
amongst users demonstrates how new patterns
of misuse can emerge, even in medicines which
have been on the market for a long period of
time.
Interpretation of Findings
A previous study reported recoveries of
83–100% codeine and 7.6–8.1% paracetamol
in solutions extracted from 20 tablets with the
use of methods from the Internet [44]. In eight
attempts of codeine extraction from 19 tablets
of codeine/paracetamol, the recovery of codeine
peaked at 71% with 9.2% of the original
amount of paracetamol left in the mixture in
the present study. However, a potential
Table 3 Contents of tampering solutions measured by LC–MS/MS
Product 1 (n5 3) Product 2 (n 5 3) Product 3 (n5 8)
S1 S2 S3 S1 S2 S3 S1 S2 S3 S4 S5 S6 S7 S8
Final volume (mL) 42 42 41 157 160 163 24 24 21 20 21 70 60 60
Substances in solutions (mg)
Codeine 92 92 95 70 75 73 74 73 62 47 65 79 75 68
Paracetamol 574 682 555 474 509 873 836 730
Acetylsalicylic acid 5851 4570 5141
Ibuprofen 205 167 132
Magnesium (Mg2?) 1180 1189 1173
Extraction recovery (%)a
Codeine 81 81 84 61 67 64 66 65 55 42 58 71 67 60
Paracetamol 6.0 7.2 5.8 5.0 5.4 9.2 8.8 7.7
Acetylsalicylic acid 73 57 64
Ibuprofen 8.5 6.9 5.5
Magnesium (Mg2?) 82 82 83
Analytical results are reported in free-base codeine
Sx sample number
a Calculated from the total amount of active substances in the tablets used for extraction
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overestimation of the amounts of codeine in
the tampering solutions procured by Fleming
et al. [44] due to poor peak resolution caused by
interference from tablet excipients may account
for the differences in findings between these
two studies.
The highest recovery of codeine from
Product 3 (codeine/paracetamol) was reached
in sample 6 where tablets were dissolved in
100 mL water instead of 40 mL used in samples
1 through 5 (Table 2). However, unlike in
previous studies [44, 45], a proportional
relationship between the volume of water and
the amounts of codeine present in the
tampering solutions was not supported by the
findings of this study. The lowest percentages
recovered of both codeine (42%) and
paracetamol (5.0%) were found in sample 4,
where the solution reached the lowest
temperature recorded in any of the tampering
products before they were taken out of the
freezer. Large crystals were observed in sample
4, but may not necessarily account for why
separation was less effective than in the other
attempts.
Following a procedure for codeine extraction
reported by users, Paterson et al. [31] removed
approximately 30% acetylsalicylic acid from ten
tablets, whereas Fleming et al. [44] removed
between 63% and 92% acetylsalicylic acid from
one tablet. Following an Internet procedure for
codeine extraction from codeine/acetylsalicylic
acid formulations, removal of acetylsalicylic
acid ranged from 27 to 43% in this study. The
findings of this and previous studies suggest
that the consumption of tampering solutions
derived from codeine/acetylsalicylic acid
preparations poses a risk of acetylsalicylic acid
poisoning, associated with interference with
thrombocyte function [57] and, in large doses,
electrolyte disturbances, dehydration, and
non-cardiogenic pulmonary edema [58–61].
Risks to Users
The study shows that multiple factors may
influence the composition of extracted
solutions, making it difficult for users to know
the quantities of drugs consumed. For this
reason, the results from this study should not
be generalised to users’ own attempts at codeine
extraction; it should not be assumed that
tampering solutions contain the same
amounts of active substances, even when
following the same procedures and using the
same codeine formulations. Imprecise
descriptions of extraction procedures in
regards to temperature, time, and volume are
part of the problem. Clotting of the coffee filters
was observed during extraction—a consequence
of using non-laboratory equipment. The use of
different materials for filtration, too, can affect
how much of each substance is left in
tampering products (the use of coffee filters,
paper tissues, t-shirt fabrics, and socks were
reported on the Internet). Finally, the recovery
percentages of both codeine and non-opioid
analgesics might also depend on the number of
tablets used for extraction. The unknown
amounts of drugs contained in tampering
solutions can result in accidental drug
overdoses from codeine and/or non-opioid
analgesics.
Tampering carries added risks when part of a
regimen of large quantities of codeine and can
lead to opioid dependence which is associated
with excessive dose consumption, tolerance,
and cravings [4, 19, 29, 62]. Additional hazards
linked to tampering of codeine include those
arising if tampering solutions are injected
intravenously as tablets contain fillers that are
safe to ingest, but dangerous when introduced
into the blood circulation [63]. For users who
drink the solutions obtained from Product 1
(codeine/acetylsalicylic acid/magnesium oxide),
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the high quantities of magnesium (Mg2?)
present an increased risk of diarrhoea. Further,
the consumption of high codeine doses could
set off the use of stronger opioids in order to
mediate aspects of tolerance and withdrawal.
Transitions from the use of prescription opioids
into heroin use have also been recorded in both
the US [64–66] and the UK [67]—although these
reports rarely involve codeine.
Policy Measures
Restrictive measures have been imposed on the
‘over-the-counter’ sale of codeine in order to
minimise misuse and dependence, including
limitations on pack size and sale (one customer,
one package), strengthened labelling and
patient information leaflet warnings, banning
of advertising, and brief pharmacy-based
interventions [24].
In addition to these regulatory steps,
however, policy measures should also involve
proactive steps in form of better surveillance of
misuse and tampering of high risk opioids. As
new trends in tampering emerge and scatter
into larger groups of users, it is of concern that
existing monitoring and early warning systems
in Europe are poorly configured to capture these
developments [5, 51]. In addition to data
commonly used to conduct risk assessments of
licensed medicines, such as adverse drug
reactions (ADRs) collected by national
medicines agencies, data on tampering and
associated harms should play a bigger role in
pharmacovigilance and regulation.
Tampering-resistant formulations have been
introduced to transition the market in order to
reduce the rates of tampering and misuse.
Tamper resistant features include (1) crush
resistance, where tablets cannot easily be
broken into a powder (2) combining an opioid
with an opioid antagonist, counteracting opioid
activity if manipulated with, and (3) tablets
forming a viscous substance when dissolved
[68, 69]. The latter strategy may be the most
suitable option in terms of preventing codeine
extraction. However, it is worth highlighting
that many tamper-resistant formulations were
introduced as substitution for potent controlled
prescription opioids, not opioids sold
‘over-the-counter’. Furthermore, concerns have
been raised that individuals thwarted by
tamper-resistant formulations turn to other
opioids instead, such as heroin, fentanyl, and
new psychoactive substances, including
acetylfentanyl and U-47700 [69, 70].
Prescribers of controlled prescription
medicines should keep in mind the potential
for tampering of certain opioids. Health
professionals should ask patients about the use
of codeine and report both tampering and harm
to public health bodies. In the UK via the Yellow
Card Scheme [71] and in Denmark with the
E-Form [72]. The lessons from the assessment of
‘cold water extraction’ procedures in this study
are that evidenced-based medicine regulation,
along with strategies to reduce harm in users and
access to appropriate treatment services, are
central components of a well-balanced public
health approach.
Limitations
The study has some limitations. Codeine was
extracted from preparations that contained
either paracetamol, ibuprofen, or
acetylsalicylic acid. However, other codeine
formulations are sold without a medical
prescription, including preparations consisting
of codeine, a non-opioid analgesic, and
caffeine, for which the results of this study do
not necessarily apply. Codeine combination
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analgesics are also supplied and sold as
prescription only medicines. In the UK,
high-strength formulations contain 30, 45, or
60 mg codeine in combination with 500 mg
paracetamol. Given the more favourable ratio of
codeine/paracetamol, compared to in
low-strength formulations, there is potentially
a higher level of attractiveness for tampering.
Tampering with these products may yield
different results and extents beyond the scope
of the study. Our findings cannot be applied to
other types of combination analgesics,
including combinations of hydrocodone/
non-opioid analgesic and oxycodone/
non-opioid analgesic [20].
It was noted that on some drug discussion
forums, codeine users reported extracting
codeine from as many as 60 tablets at a time—
three times as many as were used in this study.
Notable, increasing the number of tablets is
likely to impact the recovery percentages of
drugs in the tampering products. Lastly, the
focus of this study was on tampering methods
used by codeine taking individuals, as opposed
to specialised laboratory procedures which
could enhance the separation of codeine from
non-opioid analgesics [45]. As tampering
procedures develop over time, and considering
that specialised laboratory equipment is already
available from many shops on the Internet,
further assessment of codeine tampering is
possibly needed.
CONCLUSION
Tampering of codeine combination analgesics
allows for consumption of high doses of
codeine without consuming toxic doses of
accompanying non-opioid analgesics. The
availability of low-strength opioids without
the requirement of a medical prescription in
many European countries and elsewhere
represents incremental access to pain
medication. However, their association with
simple, yet effective tampering procedures that
are easily accessible on the Internet presents a
difficult challenge to regulators and the
pharmaceutical industry to minimise misuse.
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